TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.
Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients / A.A. Osman, D.M. Neskey, P. Katsonis, A.A. Patel, A.M. Ward, T. Hsu, S.C. Hicks, T.O. Mcdonald, T.J. Ow, M.O. Alves, C.R. Pickering, H.D. Skinner, M. Zhao, E.M. Sturgis, M.S. Kies, A. El Naggar, F. Perrone, L. Licitra, P. Bossi, M. Kimme, M.J. Frederick, O. Lichtarge, J.N. Myers. - In: CANCER RESEARCH. - ISSN 0008-5472. - 75:7(2015), pp. 1205-1215. [10.1158/0008-5472.CAN-14-2729]
Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients
F. Perrone;L. Licitra;
2015
Abstract
TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.File | Dimensione | Formato | |
---|---|---|---|
1205.full.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.23 MB
Formato
Adobe PDF
|
1.23 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.